Ocaliva® (obeticholic acid) – Safety Communication
September 21, 2017 – The FDA announced that Ocaliva (obeticholic acid) is being incorrectly dosed in some patients with moderate to severe decreases in liver function, resulting in an increased risk of serious liver injury and death.
Download PDF
